Additional file 2: of Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial

Most common (reported in ≥2 patients) treatment-emergent adverse events (safety population). (DOCX 18 kb)